Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1081-1206(10)60458-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
HSP105 inhibition downregulates store-operated calcium entry and promotes acute UVB-induced tight junction disruption.
PLoS One
December 2024
Department of Dermatology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Tight junction abnormalities are a common feature of inflammatory skin diseases such as psoriasis and atopic dermatitis and contribute to systemic immune responses. Evidence provided to date suggests that Heat shock protein 105 kDa (HSP105) exhibits significant protective effects in response to destructive external stimuli. However, its role in UV-induced skin tight junction remains to be fully understood.
View Article and Find Full Text PDFAnti-Inflammatory Effect of Ethanol Extract from L. Flower in Diesel Particulate Matter-Stimulated HaCaT Cells.
Nutrients
November 2024
Department of Oriental Pharmacy, College of Pharmacy, Wonkwang University, Iksan 54538, Republic of Korea.
Background/objectives: Diesel Particulate Matter (DPM) is a very small particulate matter originating from cities, factories, and the use of fossil fuels in diesel vehicles. When DPM permeates the skin, it causes inflammation, leading to severe atopic dermatitis. L.
View Article and Find Full Text PDFTreatment with oclacitinib, a Janus kinase inhibitor, down-regulates and up-regulates CD25 and Foxp3 expression, respectively, in peripheral blood T cells of dogs with atopic dermatitis.
BMC Vet Res
October 2024
Department of Animal Reproduction with Clinic, Faculty of Veterinary Medicine, University of Warmia and Mazury in Olsztyn, Oczapowskiego 14, 10-719, Olsztyn, Poland.
Article Synopsis
- Oclacitinib (OCL) is a Janus kinase inhibitor approved for treating atopic dermatitis (AD) in dogs, and this study aimed to evaluate its effects on T cell populations and safety in affected dogs.
- After 28 days of treatment with OCL, certain T cell counts (CD4 and CD8) showed no significant changes compared to baseline, although an increase was noted on day 7, followed by a decrease in specific subsets on days 14 and 28.
- The study concluded that OCL treatment appears safe regarding T cell counts and suggests its therapeutic benefits may come from lowering eosinophil levels and reducing CD25 expression on CD4 Teff cells linked to AD.
Impact of Dupilumab on Skin Surface Lipid-RNA Profile in Severe Asthmatic Patients.
Curr Issues Mol Biol
October 2024
Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo 113-8421, Japan.
The analysis of skin surface lipid-RNAs (SSL-RNAs) provides a non-invasive method for understanding the molecular pathology of atopic dermatitis (AD), but its relevance to asthma remains uncertain. Although dupilumab, a biologic drug approved for both asthma and AD, has shown efficacy in improving symptoms for both conditions, its impact on SSL-RNAs is unclear. This study aimed to investigate the impact of dupilumab treatment on SSL-RNA profiles in patients with severe asthma.
View Article and Find Full Text PDFInflammatory Mediators Suppress FGFR2 Expression in Human Keratinocytes to Promote Inflammation.
Mol Cell Biol
October 2024
Institute of Molecular Health Sciences, Department of Biology, ETH Zürich, Zürich, Switzerland.
Fibroblast growth factors (FGFs) are key orchestrators of development, tissue homeostasis and repair. FGF receptor (FGFR) deficiency in mouse keratinocytes causes an inflammatory skin phenotype with similarities to atopic dermatitis, but the human relevance is unclear. Therefore, we generated human keratinocytes with a CRISPR/Cas9-induced knockout of .
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!